D&D Pharmatech's New Drug Candidate Approved for Phase 2 Clinical Trial in Multiple Sclerosis in the U.S.
The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the Phase…
D&D Pharmatech
2 개의 기사가 있습니다.
D&D Pharmatech "Confident in MASH and Obesity Drug Efficacy…Targeting 100 Trillion Won Market"
“The GLP-1 obesity treatment market is expected to grow to 100 trillion won( approximately 77 billion dollars) by…